Biomedicines 7 , 5
URL: CATEGORIES:School ATTACH;FMTTYPE=image/jpeg: END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20200424T052534 DTEND;TZID=UTC:20200401T170000 DTSTAMP:20260728T071445 CREATED:20170208T071226Z LAST-MODIFIED:20170208T071226Z UID:[email protected] SUMMARY:Open Day DESCRIPTION:The Ed School District is in compliance with the U.S
Comparative Bioavailability Table This bioavailability difference means that a 250mcg nasal spray dose might deliver similar systemic exposure to a 500mcg oral dosean important consideration for both efficacy and cost-effectiveness
Drugs ORAL HYPOGLYCEMICS: : glyburide, glipizide, glimepiride Sulfonylureas : repaglinide, nateglinide Glinides : metformin Biguanide : acarbose, miglitol -Glucosidase Inhibitors Thiazolidinediones or : pioglitazone, rosiglitazone Glitazones 1) : bromocriptine Dopamine agonist : canagliflozin, dapagliflozin, empagliflozin SGLT-2 Inhibitors : sitagliptin, saxagliptin, linagliptin, alogliptin DPP-IV Inhibitors INJECTIBLE HYPOGLYCEMICS : : exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide GLP-1 Agonists : pramlintide Amylin Analog BILE ACID SEQUESTRANTS: colesevelam INSULINS: PRANDIAL: : lispro, aspart, glulisine, inhaled Rapid acting : regular crystalline zinc Short-acting BASAL: : NPH (or Isophane) Intermediate acting : glargine, detemir Long acting : degludec Ultra-long acting INSULIN + GLP1 COMBINATIONS: glargine + lixisenatide (Soliqua ) degludec + liraglutide (Xultophy ) GOALS OF THERAPY Figure X
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder, and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality
Constante M, et al
